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Background: Acinetobacter baumannii is an opportunistic pathogen posing an increased risk to hospitalized
persons, causing nosocomial pneumonias, urinary tract infections and postoperative infections.
Methods: Between 1 December 2011 and 30 September 2012, strains of Acinetobacter spp. were isolated from
clinical samples obtained from hospitalized patients. Susceptibility to antibiotics was determined by the standard
microdilution method and phenotypic testing was used to detect the presence of serine carbapenemases and
metallo-beta-lactamases. The polymerase chain reaction was used to detect the genes encoding carbapenemases.
Pulsed field gel electrophoresis was used to investigate the genetic relationship among the carbapenem resistant
isolates of Acinetobacter baumannii.
Results: In three strains of Acinetobacter baumannii enzyme OXA-23 was detected. This positive result was
confirmed by restriction analysis and sequencing. The study reported an OXA-23-producing strains of Acinetobacter
baumannii in the Czech Republic. All three strains isolated from Military Hospital patients had a completely identical
restriction profile, indicating clonal spread of a strain carrying serine carbapenemase OXA-23 in this health care
facility. Moreover this was the first time the strain was detected in the country in patients who had not stayed
abroad.Background
At present, one of the most serious issues in medicine is
increasing resistance of bacterial pathogens to anti-
microbial agents. This fact is associated with higher
mortality and morbidity rates, prolonged hospital stays
and increased treatment-related costs (Rello et al., 1994;
Scaife et al., 1995; Luna et al., 1997; Micek et al., 2005;
Uvizl et al., 2011; Trecarichi et al. 2011). Such negative
trends have also been observed in Acinetobacter spp.
strains. Together with isolates of Pseudomonas aeruginosa,
Stenotrophomonas maltophilia and Burkholderia cepacia
complex, these belong to the clinically most important
aerobic non-fermenting Gram-negative rods. The species
Acinetobacter baumannii is an opportunistic pathogen
with increasing clinical significance, particularly in im-
munocompromised patients, causing nosocomial infec-
tions of the lungs, urinary tract and surgical wounds (Lee
et al., 2009).* Correspondence: marketa.senkyrikova@klikni.cz
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reproduction in any medium, provided the origMoreover, the role of Acinetobacter baumannii is
strengthened by relatively high resistance to numerous
antibiotics which is determined by both natural and ac-
quired mechanisms (Jeon et al., 2005). In multiresistant
strains of Acinetobacter baumannii, the drugs of choice
are carbapenems. Unfortunately, the development of re-
sistance did not spare even this group of antimicrobial
drugs, with the main mechanism being production of
carbapenemases, enzymes belonging to Ambler classes
B, A and D (Ambler, 1980; Bush et al., 2010). From class
B carbapenemases known as metallo-beta-lactamases
(MBLs), were in Acinetobacter spp. strains detected type
of IMP, VIM and SIM enzymes (Zarrilli et al., 2009).
However, resistance of Acinetobacter baumannii to car-
bapenems is more frequently caused by production of
class D serine carbapenemases. These enzymes are
called carbapenem-hydrolyzing class D beta-lactamases
(CHDLs) (Higgins et al., 2010). The first reported ac-
quired class D beta-lactamases with carbapenemase in
Acinetobacter baumannii originated from Scotland and
is known as OXA-23 (initially refered as ARI-1) (Scaife
et al., 1995; Mugnier et al., 2010). The most commonis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and







Figure 1 CD test for class A carabapenemase detection. Legend:
3-APB - 3-aminophenylboronic acid.
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OXA-23, OXA-24/40 OXA-58, OXA-143 and OXA-51
(Dijkshorn et al., 2007; Higgins et al., 2009). The gene
for OXA-51 is located on a chromosome and, unlike the
other OXA types able to hydrolyze carbapenems, it has
a very low level of expression and does not cause resist-
ance (Dijkshorn et al., 2007).
Nowadays CHDLs are spread worldwide and they are
often involved in nosocominal infection (Peleg et al.,
2008). Isolates carrying CHDLs were detected in North
and South America (Peleg et al., 2008; Villegas et al.,
2007; Merkier et al., 2008; Dalla-Costa et al., 2003;
Lolans et al., 2006), Africa (Marais et al., 2004), Australia
(Peleg et al., 2006), Asian area like China (Zong et al.,
2008; Hsueh et al., 2002) Korea (Kim et al., 2008),
Thailand (Mendes et al., 2009), Indonesia (Mendes et al.,
2009) and also in European countries like the United
Kigdom (Coelho et al.; 2006), the Netherlands (van den
Broek et al., 2006), France (Corvec et al., 2007), Belgium
(Wybo et al., 2007), Burglaria (Stoeva et al., 2008),
Belgium (Bogaerts et al., 2006), Greece (Tsakris et al.,
2008) or Spain (Acosta et al., 2011).
It must be stressed that resistance of Acinetobacter
spp. to carbapenems may be caused by other mecha-
nisms such as changes in porin expression, modification
of PBPs or efflux of an antibiotic from a cell (Poirel
et al., 2010).
Carbapenem resistance in Acinetobacter baumannii
associated with OXA-type enzymes was first occurred in
2008 in the Czech republic. There were detected OXA-
58-like and OXA-24-like enzymes from patients hospi-
talized at intensive care units (Nemec et al., 2008). Then
a few years later in 2011 was in the Czech republic
detected a multiresistant strain of Acinetobacter
baumannii carrying the genes for NDM-1 and OXA-23
was detected in 2011 (Křížová et al., 2012). However, this
strain was isolated in a patient who had returned from a
stay in Egypt and belonged to the European (EU) clone I
(Křížová et al., 2012).
This is the first report in the Czech Republic of
Acinetobacter baumannii strains producing OXA-23 iso-
lated from a patient who did not stay abroad.
Material and methods
Strain selection
Between 1 December 2011 and 30 September 2012,
Acinetobacter spp. strains were isolated from clinical
samples (endotracheal secretion, bronchoalveolar lav-
age, sputum, blood, urine, pus, aspirate, wound secre-
tion, blood culture). These strains were obtained from
patients hospitalized at intensive care units in the
University Hospital Olomouc and Military Hospital
Olomouc. The identification was performed by standard
microbiology procedures including the use of thePhoenix automated system (Becton, Dickinson and Com-
pany) and MALDI-TOF Biotyper (Bruker Daltonics).
Determining resistance to antimicrobial agents
In all Acinetobacter spp. isolates, susceptibility to antibi-
otics was determined by a standard microdilution method
according to the EUCAST (European Committee on Anti-
microbial Susceptibility Testing) criteria (European Com-
mittee on Antimicrobial Susceptibility Testing, 2012). The
reference strains for quality controls were Escherichia coli
ATCC 25922, Escherichia coli ATCC 35218 and Pseudo-
monas aeruginosa ATCC 27853. Resistance to meropenem
determined by the microdilution method was confirmed
by the E-test (bioMérieux, France). In case of imipenem
and ertapenem, the E-test was also used to determine the
minimum inhibitory concentrations (MIC).
Phenotypic determination of carbapenemase production
Carbapenemase production in Acinetobacter spp. isolates
with a MIC for meropenem of >2 mg/L was phenotypic-
ally determined by the CD test (Figure 1) for detection
of carbapenemases class A, combined disc (Figure 2)
and modified Hodge test for serine carbapenemases and
MBL detection (Lee et al., 2009; Pasteran et al., 2009;
Pournaras et al., 2010).
Genotypic determination of carbapenemase production
In Acinetobacter baumannii strains with a MIC for
meropenem of >2 mg/L, positively phenotypically tested
for carbapenemase, the relevant genes were determined.
This was carried out by PCR using specific oligonucleo-
tide primers encoding serine carbapenemases of class A












Figure 2 Combined test for serine carbapenemases and
metallo-beta-lactamase detection. Legend: EDTA –
ethylenediaminetetraacetic acid.
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primers for amplification are shown in Table 1. The
positive control was a strain with a known content of
carbapenemases (producing KPC-2 enzyme) provided
by Ing. J. Hrabák, Ph.D. from the Department of Micro-
biology, Faculty of Medicine in Pilsen, Charles Univer-
sity in Prague.
Strains selected for gene detection were inoculated

















Legend: Ta – annealing temperature.aerobically cultured at 37°C for 18 hours. 1–2 colonies
from this fresh culture were resuspended in 100 μL of
sterile water and heated at 95°C for 10 minutes. This was
followed by centrifugation at 13,000×g for 2 minutes. The
obtained supernatant served as a template for subsequent
PCR using the Robocycler Gradient 96 Temperature Cy-
cler with specific primers shown in Table 1.
The obtained amplicons were subsequently separated
on 1.5% agarose gel and compared with a DNA molecu-
lar weight marker (Top-Bio, Czech Republic). Then,
OXA-23-positive PCR products were cleaved with the
HphI restriction endonuclease (New England Biolabs,
Great Britain) and separated on 1.5% agarose gel, with
cleaved fragment sizes being compared with the molecu-
lar weight marker. The amplified gene sequence was
confirmed by direct sequencing of a PCR amplicon pro-
vided by Elisabeth Pharmacon (Czech Republic) and by
comparing the obtained DNA sequence in BLAST (Basic
Local Alignment Searching Tool, National Center for
Biotechnology Information, www.ncbi.nlm.nih.gov).
Determination of epidemiological relationship
To determine epidemiological relationship of strains with
positive genotypic assay results, macrorestriction profiles
of genome DNA were compared by pulsed-field gel elec-
trophoresis (PFGE).
The PFGE analysis was carried out with bacterial DNA
isolated from culture freshly grown on Mueller Hinton
broth as described previously (Husičková et al., 2012).
Bacterial DNA was then cleaved with the SmaI restric-
tion endonuclease (Takara, Japan). The restriction frag-




1138 50°C Radice et al.; 2004
818 50°C Queenan et al.; 2000
2158 50°C Aubron et al.; 2005
893 60°C Bradford et al.; 2004
371 50°C Weldhagen et al.; 2004
1066 50°C Donald et al.; 2000
744 50°C Poirel et al., 2004
Figure 3 Resistance of Acinetobacter spp. to selected antimicrobial agents (percentages).





21678/C 12 16 >32
12257/C >32 16 >32
15848/C >32 >32 >32
E-test MICs testing.
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tions: 5 V/cm, switch interval 2–20 seconds, for 20 hours
at 14°C in 0.5 × TBE buffer. The gel was stained with eth-
idium bromide at 0.75 μg/ml for 1 h and visualized by UV
transllumination. A 50–1,000 kb Pulse marker (Sigma,
USA) was used to determine the size of DNA fragments.
The PFGE results were analysed with GelCompar II (Ap-
plied Maths) software.
Results
Over the study period, a total of 166 Acinetobacter spp.
strains were isolated in the two participating hospitals.
Figure 3 shows the resistance to antimicrobial agents in
a group of 140 isolates assumed to play a role in the eti-
ology of the particular infection. The results revealed a
prevalence of meropenem-resistant strains of 10.7%.
From the group of 140 strains, a total of 15 strains
were found to be resistant to meropenem using the stand-
ard microdilution method. The phenotypic assay demon-
strating production of carbapenemases (modified Hodge
test) was positive in 3 strains. In these 3 strains, MICs to
selected antimicrobial agents (ertapenem, imipenem and
meropenem) were determined by the E-test, as shown in
Table 2.
All the three Acinetobacter baumannii strains origi-
nated from the Military Hospital. Strain no. 21678/C
was isolated from blood culture of a patient with blood-
stream infection staying at a department of anesthesiology
and intensive care medicine. Samples nos. 12257/C and
15848/C were isolated from endotracheal secretions col-
lected from two patients with late-onset ventilator-
associated pneumonia hospitalized at a department of
chronic intensive care.
Genetic determination of the presence of resistance
genes confirmed the presence of a gene encoding class
D carbapenemase, namely OXA-23 enzyme in all three
strains. Restriction fragment length polymorphism ana-
lysis in positive PCR amplicons and final confirmationby direct sequencing showed the presence of OXA-23
enzyme in all three Acinetobacter baumannii strains.
Comparison of macrorestriction profiles of genomic
DNA using PFGE revealed that the strains had an identi-
cal restriction profile. This suggested clonal spread of a
genetically identical strain.
Discussion
Class D serine carbapenemase in an Acinetobacter
baumannii strain was first reported in Scotland in 1985,
that is, before imipenem started to be widely used in
clinical practice (Paton et al., 1993; Carvalho et al.,
2011). This enzyme, originally called ARI-I, was se-
quenced and subsequently labeled as OXA-23 (Scaife
et al., 1995; Mugnier et al., 2010).
Until now, this enzyme has been reported in
Acinetobacter baumannii strains throughout the world
(Mugnier et al., 2010).
In the Czech republic a multiresistant strain of
Acinetobacter baumannii carrying the genes for NDM-1
and OXA-23 was detected in 2011. However, this strain
was isolated in a patient who had returned from a stay
in Egypt and belonged to the European (EU) clone I
(Křížová et al., 2012). Thus, the above description of
Acinetobacter baumannii strains producing OXA-23 is
their first report in the Czech Republic in patients who
did not stay abroad, suggesting their domestic origin.
All three strains isolated from Military Hospital patients
had a completely identical restriction profile, indicating
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OXA-23 in this health care facility.
Increasing resistance of bacterial pathogens to anti-
microbial agents poses a severe threat to management of
many infections. Of particular risk is the rise in the use
of carbapenems resulting from a high prevalence of
ESBL- and AmpC-positive Enterobacteriaceae which
may determine the development of resistance to this
group of still effective drugs (Coelho et al., 2004). Our
data suggest that in the case of Acinetobacter spp.
strains, the prevalence of carbapenem-resistant isolates
is low. However, this situation needs to be carefully
monitored and if this type of resistance spreads it must
be adequately analyzed using modern molecular biology
methods.
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